Abstract
α-Adrenoceptors, 425
5′,10′-methylenetetrahydrofolate reductase (MTHFR), 491
5-HT1 receptor, 2, 398
5-HT1A receptors, 99
5-HT1B/1D agonist, 288
5-HT1B/1D receptors, 99
5-Hydroxytryptamine, 466
abulatory accelerometry, 271
academic, 522
acetylsalicylic acid, 947
actigraphy, 134
acute attack treatment, 707
acute mountain sickness, 66
acute sensitization, 925
acute therapy, 888
acute treatment, 356
adolescent, 54
adolescent psychology, 54
adolescents, 12, 120, 288, 373
adults, 12
agatoxin, 250
aggregation, 586
allodynia, 735, 1057
almotriptan, 288
anaemia, 758
analgesic overuse, 850
analgesics, 321
angina pectoris, 92
angiography, 515
anti-β2 glycoprotein I antibodies, 831
anticardio-lipin antibodies, 831
antiphospholipid antibodies, 831, 1024
arteriovenous anastomoses, 425
aura, 18, 503, 728, 985
benign cough headache, 694
BIBN 4096 BS, 646
bilateral headache, 52
blink reflex, 44, 657
botulinum toxin, 675
botulinum toxin A, 60, 838
bradykinin, 466
brain organization, 339
burden, 455
caffeine-withdrawal headache, 241
calcitonin gene-related peptide, 646
cAMP, 547
capsaicin, 717
cardiac output, 425
carotid haemodynamics, 717
catalase, 37
catecholamine (noradrenaline), 1077
caudal spinal trigeminal nucleus, 439
cavum septi pellucidi, 867
CBF, 576, 1077
central auditory processing, 663
central sensitization, 161, 735
cerebellar, 83
cerebral haemodynamics, 700
cerebral oedema, 66
cerebral venous congestion, 973
cervicogenic headache, 821
cGMP, 547
CGRP, 547, 611, 717
CGRP blockers, 611
chemodenervation, 60
chest symptoms, 298
Chiari malformation, 694, 883
child development, 54
childhood, 554, 831
children, 12, 120, 134, 333, 380, 476
chloroquine, 1031
chronic, 1045
chronic daily headache, 54, 60, 446, 476, 484, 495, 850
chronic migraine, 735
chronic paroxysmal hemicrania, 52, 173
chronic tension-type headache, 29, 675, 967
citrulline, 967
classification, 940
clinical characteristics, 1016
clinical features, 12
clinical trial, 321, 347
clinical trials, 586
cluster headache, 92, 110, 185, 188, 206, 280, 611, 631, 753, 859, 934, 938, 1045, 1049
CNS, 417
coffee, 241
cognitive processing, 554
co-morbidity, 850
computer-aided pressure algesimetry, 1067
conotoxin, 250
contrast sensitivity, 389
cortical blood flow, 206
CPH, 753
CSF, 735
cumulative organ damage, 1024
daily functioning, 271
data analysis, 586
data mining, 586
deep brain stimulation, 934
deficient habituation, 663
diagnosis follow-up, 850
diagnostic support, 110
diffuse noxious inhibitory controls, 44
diffusion weighted imaging, 66
disability, 120
dizziness, 83
door-to-door survey, 960
dopamine D2 receptor gene, 503
drug interaction, 875
drug overuse, 398
eagle syndrome, 411
early intervention, 925
education, 522
eletriptan, 515
endothelin, 639
epidemiology, 197, 455, 631, 960
episodic, 1045
episodic tension-type headache, 29, 293
ergotamine, 321
event-related potentials, 554
exertional headache, 867
experimental, 576, 875, 1077
facet joint, 821
familial, 564
familial hemiplegic migraine, 533
familial occurrence, 938
family history of migraine, 339
ferritin, 758
fibromyalgia, 735
flicker frequency, 408
flunarizine, 528
fMRI, 753
folate metabolism, 491
follow-up, 18
France, 197
frontal lobe epilepsy, 23
frovatriptan, 1045
fTCD, 700
functional disability, 844
GABA, 250
gabapentin, 993
genetic, 503, 938
genetics, 564, 1016
glutamate, 735
glutamate receptors, 596
glutathione peroxidase, 37
glyceryl trinitrate, 92, 967
glyceryltrinitrate, 576, 875, 1077
grading of headache, 241
graine, 271
haemodialysis, 284
haemodialysis-related headache, 284
haemoglobin, 758
headache, 2, 29, 60, 120, 197, 241, 262, 284, 356, 373, 380, 408, 476, 522, 540, 576, 586, 728, 740, 758, 875, 940, 980, 985, 1031, 1077
headache model, 576, 1077
headaches, 844
health care seeking behaviour, 740
health-related quality of life, 188
healthy volunteers, 646
hemicrania continua, 173, 603
high al-titude, 66
histamine, 466
human, 280, 576, 875, 1077
human experimental muscle pain, 466
Hürthle cell carcinoma, 411
hyperalgesia, 1057
hyperbaric oxygen therapy, 639
hypotension, 875
hypothalamus, 934
ibuprofen, 947
ice-cream headache, 293
idiopathic intracranial hypertension, 495
idiopathic stabbing headache, 993
IHS criteria, 12, 380, 960
indomethacin, 52, 173
ingestion of cold stimulus, 293
inheritance, 564
interferon, 980
interictal, 271
internal jugular venous blood, 623
International Headache Society criteria, 980
interview, 938
intracranial pressure monitoring, 495
lacrimation, 206
lidocaine, 985
lifetime prevalence, 980
light, 128
light stimuli, 408
lipid peroxidation by-products, 528
lupus anticoagulant, 831
LY293558, 596
lysine acetylsalicylate, 439
major depression, 339
medication overuse, 484
melatonin, 128
meningeal blood flow, 206
meninges, 250
menstrual cycle, 707
menstrually related migraine, 707
microdialysis, 161
microspheres, 425
migraine, 2, 12, 18, 23, 37, 44, 83, 99, 110, 128, 134, 197, 262, 288, 293, 333, 339, 356, 373, 380, 389, 408, 411, 425, 455, 476, 503, 515, 528, 540, 547, 576, 586, 596, 611, 639, 657, 663, 717, 728, 758, 831, 838, 875, 888, 894, 918, 925, 940, 947, 960, 973, 980, 1024, 1031, 1049, 1057, 1077
migraine-specific quality of life questionnaire (MSQ2.1), 188
migraine therapy, 347
migraine triggers, 408
migraine with aura, 491, 564, 700
migraine with typical aura, 1016
migraine without aura, 554, 707
migraine without aura attacks, 623
MIGSEV, 262
mismatch negativity, 663
modes of treatment, 925
mood, 271
motion sickness, 44, 83
MR myelography, 883
MRI, 533, 694, 867
muscle tenderness, 161
myofascial pain, 446
naratriptan, 99, 586
neck pain, 821, 1067
neurological model, 875
neutrophils, 37
new daily persistent headache, 867, 955
nimodipine, 250
nitrates, 92
nitric oxide, 92, 161, 528, 576, 875, 967, 1077
nitric oxide synthase, 439
nitroglycerin, 110, 439, 576, 875, 1077
nociceptin, 280
non-lateralized pain, 52
non-steroidal medication, 321
occipital lobe epilepsy, 23
OP-4 receptor, 280
optimizing treatment, 918
organic headache, 173
osmophobia, 940
oxidative stress, 37
pachymeningeal enhancement, 883
paediatric, 850
paediatric disorders, 844
paediatric psychology, 120
pain, 2, 844
pain quantification, 1067
pain relief, 540
papilledema, 495
parasympathetic system, 206
parents, 120
paroxysomal hemicrania, 859
pathophysiological considerations, 1016
patient preference, 347
perimetry, 389
persistent aura, 533
pharmacists, 740
pharmacokinetics, 288, 646
pharmacological treatment, 955
pharmacology, 576, 875, 1077
phenazone, 888
physiotherapy, 29
placebo, 947
placebo-controlled randomized study, 888
plasma, 547
platelet-activating factor, 623
platelet-activating factor acetylhydrolase, 623
polymorphism, 503
postictal headache, 23
postpartum, 603
postural headache, 883
prazosin, 425
prevalence, 373, 380, 669, 960
preventive, 1049
preventive treatment, 29
primary care, 740
primary cough headache, 694
prognosis, 18
prophylactic treatment, 356, 838
propranolol, 1077
prostaglandin E2, 466
protein extravasation, 398
provocative test, 110
psychiatric, 850
psychological factors, 446
psychosocial factors, 669
quality of life, 262, 455, 844
Queckenstedt's test, 973
questionnaire, 894
R2, 44
radiofrequency neurotomy, 821
randomized controlled crossover trial, 947
randomized controlled trial, 596
rauwolscine, 425
reaction times, 554
recursive partitioning, 586
rheumatoid arthritis, 1031
risk, 938
risk factor, 54
risk factors, 740
rizatriptan, 540
S19014, 425
safety, 646
SB-220453, 875
screening, 894
sensory thresholds, 1057
severity, 262
short attacks, 333
short-form health survey (SF-36), 188
shunt, 495
side effects, 417
sildenafil, 547
sleep, 134
sleep quality, 446
South Tanzania, 960
specialty practice, 522
SPECT, 533
spontaneous CSF leak, 883
sporadic hemiplegic migraine, 1016
statistics, 586
sumatriptan, 439, 515, 540, 586, 717, 925, 947
SUNCT, 753
SUNCT syndrome, 173, 859, 985
sunshine duration, 631
superoxide dismutase, 37
supersensitivity, 128
surgery, 934, 894
Sweden, 455
symptomathology, 564
systemic lupus erythematosus, 1024, 1031
Taiwan, 631
taste abnormalities, 940
temporal lobe epilepsy, 23
temporomandibular joint pain, 446
tension-type headache, 29, 161, 373, 380, 476, 669
therapy, 934
Tonerbasat, 875
topiramate, 985
transcranial Doppler, 1077
transcranial doppler, 576
transformed migraine, 484
treatment, 993
treatment outcome, 484
trigeminal autonomic cephalgia, 753
trigeminal autonomic cephalgias, 859
trigeminal neuralgia, 753
trigeminal nociception, 657
trigeminal nucleus caudalis, 99
trigeminal sensitization, 44
trigem-ino-autonomic cephalgias, 185
trigeminovascular, 1049
trigeminovascular reflex, 611
trigeminovascular system, 280
triptan, 398
triptans, 197, 298, 321, 417, 1057
tryptophan hydroxylase, 2
Turkish-students, 669
under-treatment, 356
unilateral headaches, 185
validation, 894
valproate, 576
valsalva manoeuvre, 185
vasoconstriction, 298, 398, 425, 515
vertigo, 83
VIP, 611
visual, 728
visual fields, 389
visual stimulation, 700
whiplash injury, 1067
yawning, 411
young patients, 993
young population, 669
zolmitriptan, 918